Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 56, Issue 6

Issues

Abiraterone acetate: a potential source of interference in testosterone assays

Benjamin P. Fairfax
  • Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Robert D. Morgan
  • Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Andrew Protheroe
  • Corresponding author
  • Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Brian Shine
  • Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Timothy James
  • Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-01-05 | DOI: https://doi.org/10.1515/cclm-2017-0631

References

  • 1.

    Cancer Research UK Prostate Cancer Statistics, 2014.Google Scholar

  • 2.

    Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(S5):v69–77.Web of ScienceCrossrefPubMedGoogle Scholar

  • 3.

    Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 4.

    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.CrossrefPubMedGoogle Scholar

  • 5.

    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368: 138–48.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 6.

    Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. Clinical and biochemical consequences of cyp17a1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507–16.PubMedWeb of ScienceCrossrefGoogle Scholar

About the article

Corresponding author: Professor Andrew Protheroe, PhD FRCP, Department of Oncology, Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Headington, Oxford OX3 7LE, UK, Phone: +44(0) 1865 235275


Received: 2017-07-17

Accepted: 2017-11-27

Published Online: 2018-01-05

Published in Print: 2018-05-24


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 56, Issue 6, Pages e138–e140, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2017-0631.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in